Pioneering Gene Therapies for Patients in Need


Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.


We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, Reqorsa® Immunogene Therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer and small cell lung cancer.

Management Team

We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us

At Genprex, we are committed to developing life-changing gene therapies for patients afflicted with cancer and diabetes. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease. 

What they’re saying

In the Media

Catch up with our

Latest News

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Company Achieves Multiple Clinical Development Milestones in 2024

Genprex to Present at the 2024 BIO International Convention

Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes

Acclaim-3 Dosing Begins: Quaratusugene Ozeplasmid/Atezolizumab in ES-SCLC

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024